Abstract

Amyloidogenesis is known to cause Alzheimer’s disease. Our previous studies have found that lipopolysaccharide (LPS) causes neuroinflammation and amyloidogenesis through activation of nuclear factor kappaB (NF-κB). Piperlongumine (PL) is an alkaloid amide found naturally in long pepper (Piper longum) isolates; it was reported to have inhibitory effects on NF-κB activity. We therefore investigated whether PL exhibits anti-inflammatory and anti-amyloidogenic effects by inhibiting NF-κB. A murine model of LPS-induced memory impairment was made via the intraperitoneal (i.p.) injection of LPS (0.25 mg/kg/day, i.p.). We then injected PL (1.5 or 3.0 mg/kg/day, i.p.) for 7 days in three groups of mice to observe effects on memory. We also conducted an in vitro study with astrocytes and microglial BV-2 cells, which were treated with LPS (1 µg/mL) or PL (0.5 or 1.0 or 2.5 µM). Results from our behavioral tests showed that PL inhibited LPS-induced memory. PL also prevented LPS-induced beta-amyloid (Aβ) accumulation and inhibited the activities of β- and γ-secretases. The expression of inflammatory proteins also was decreased in PL-treated mice, cultured BV-2, and primary astrocyte cells. These effects were associated with the inhibition of NF-κB activity. A docking model analysis and pull-down assay showed that PL binds to p50. Taken together, our findings suggest that PL diminishes LPS-induced amyloidogenesis and neuroinflammation by inhibiting NF-κB signaling; PL therefore demonstrates potential for the treatment of Alzheimer’s disease.

Highlights

  • Alzheimer’s disease (AD) accounts for about 50–75% of dementia cases (Prince et al 2014); it is characterized by a deterioration of memory, language, problem-solving, and other cognitive skills that affect an individual’s ability to perform everyday activities (American Psychiatric Association 2013)

  • These symptoms are primarily caused by the damage and death of neurons, a phenomenon exacerbated by the accumulation of beta-amyloid (Aβ); Aβ is produced from amyloid precursor protein (APP) by β-site APP cleaving enzyme (BACE1) and γ-secretase (Li and Buxbaum 2011; LaFerla et al 2007)

  • NeuroMolecular Medicine (2018) 20:312–327 a significant role in the etiology of AD: a significantly increased quantity of COX-2-positive cells was found in the brains of patients with AD (Fiala et al 2002), a significant rise in NOS activity was observed in microvessels isolated from the brains of patients with AD (Dorheim et al 1994), an increase in mRNA levels of inducible inducible nitric oxide synthase (iNOS) was found within the cortices of AD patients (Dorheim et al 1994; Haas et al 2002), and the levels of proinflammatory cytokines (TNF-α, IL-1β and IL-6) were reportedly higher in the plasma or cerebrospinal fluid (CSF) of AD patients than that of controls (Licastro et al 2000; Alvarez et al 1996, 2007; Tarkowski et al 1999)

Read more

Summary

Introduction

Alzheimer’s disease (AD) accounts for about 50–75% of dementia cases (Prince et al 2014); it is characterized by a deterioration of memory, language, problem-solving, and other cognitive skills that affect an individual’s ability to perform everyday activities (American Psychiatric Association 2013). These symptoms are primarily caused by the damage and death of neurons, a phenomenon exacerbated by the accumulation of beta-amyloid (Aβ); Aβ is produced from amyloid precursor protein (APP) by β-site APP cleaving enzyme (BACE1) and γ-secretase (Li and Buxbaum 2011; LaFerla et al 2007). The generation and accumulation of Aβ is closely associated with the neuroinflammatory response

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call